118 related articles for article (PubMed ID: 2604753)
1. Mechanism of antiatherogenic action of calcium antagonists.
Jackson CL; Bush RC; Bowyer DE
Atherosclerosis; 1989 Nov; 80(1):17-26. PubMed ID: 2604753
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of calcium antagonists on balloon catheter-induced arterial smooth muscle cell proliferation and lesion size.
Jackson CL; Bush RC; Bowyer DE
Atherosclerosis; 1988 Feb; 69(2-3):115-22. PubMed ID: 3348836
[TBL] [Abstract][Full Text] [Related]
3. The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation.
Nilsson J; Sjölund M; Palmberg L; Von Euler AM; Jonzon B; Thyberg J
Atherosclerosis; 1985 Dec; 58(1-3):109-22. PubMed ID: 3004518
[TBL] [Abstract][Full Text] [Related]
4. Antiatherogenic activity of FR34235 (Nilvadipine), a new potent calcium antagonist. Effect on cuff-induced intimal thickening of rabbit carotid artery.
Nomoto A; Hirosumi J; Sekiguchi C; Mutoh S; Yamaguchi I; Aoki H
Atherosclerosis; 1987 Apr; 64(2-3):255-61. PubMed ID: 3606723
[TBL] [Abstract][Full Text] [Related]
5. Calcium antagonists and vascular smooth muscle cells in atherogenesis.
Pauletto P; Sartore S; Giuriato L; Scatena M; Tonello M; Scannapieco G; Pessina AC; Dal Palù C
J Cardiovasc Pharmacol; 1992; 19 Suppl 2():S8-16. PubMed ID: 1377310
[TBL] [Abstract][Full Text] [Related]
6. Influence of nifedipine on experimental arteriosclerosis.
Knorr AM; Kazda S
Cardiovasc Drugs Ther; 1990 Aug; 4 Suppl 5():1027-31. PubMed ID: 2076389
[TBL] [Abstract][Full Text] [Related]
7. Nifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK pathway coupling with Pyk2.
Hirata A; Igarashi M; Yamaguchi H; Suwabe A; Daimon M; Kato T; Tominaga M
Br J Pharmacol; 2000 Dec; 131(8):1521-30. PubMed ID: 11139427
[TBL] [Abstract][Full Text] [Related]
8. Antiatherosclerotic effects of calcium antagonists. Study in human aortic cell culture.
Orekhov AN; Baldenkov GN; Tertov VV; Ruda MYa ; Khashimov KA; Kudryashov SA; Ryong LH; Kozlov SG; Lyakishev AA; Tkachuk VA
Herz; 1990 Apr; 15(2):139-45. PubMed ID: 1971612
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacologic inhibition of experimental atherosclerosis].
Seuter F
Z Kardiol; 1989; 78 Suppl 6():117-9. PubMed ID: 2618127
[TBL] [Abstract][Full Text] [Related]
10. Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbit arterial smooth muscle cells. A possible mechanism for its antiatherogenic effect.
Etingin OR; Hajjar DP
J Clin Invest; 1985 May; 75(5):1554-8. PubMed ID: 3923040
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of the inhibitory effect of nifedipine on the growth of cultured aortic cells from spontaneously hypertensive and normotensive rats.
Hérembert T; Zhu DL; Marche P
Br J Pharmacol; 1995 Apr; 114(8):1703-9. PubMed ID: 7541285
[TBL] [Abstract][Full Text] [Related]
12. Calcium antagonists in experimental atherosclerosis. Use-dependence of isradipine: a potential explanation for enhanced action in atherosclerotic animals and tissue selectivity.
Hof RP; Rüegg UT
Am J Hypertens; 1991 Feb; 4(2 Pt 2):107S-113S. PubMed ID: 1826999
[TBL] [Abstract][Full Text] [Related]
13. Nifedipine inhibits vascular smooth muscle cell proliferation and reactive oxygen species production through AMP-activated protein kinase signaling pathway.
Sung JY; Choi HC
Vascul Pharmacol; 2012; 56(1-2):1-8. PubMed ID: 21708289
[TBL] [Abstract][Full Text] [Related]
14. Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations.
Fleckenstein-Grün G; Thimm F; Czirfuzs A; Matyas S; Frey M
J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S75-84. PubMed ID: 7898099
[TBL] [Abstract][Full Text] [Related]
15. Vascular injury: mechanisms and manifestations.
Nayler WG
Am J Med; 1991 Apr; 90(4B):8S-13S. PubMed ID: 1826808
[TBL] [Abstract][Full Text] [Related]
16. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth.
Igarashi M; Takeda Y; Mori S; Ishibashi N; Komatsu E; Takahashi K; Fuse T; Yamamura M; Kubo K; Sugiyama Y; Saito Y
Br J Pharmacol; 1997 Mar; 120(6):1172-8. PubMed ID: 9134232
[TBL] [Abstract][Full Text] [Related]
17. Use of cultured atherosclerotic cells for investigation of antiatherosclerotic effects of anipamil and other calcium antagonists.
Orekhov AN; Tertov VV; Lyakishev AA; Ruda MYa
J Hum Hypertens; 1991 Oct; 5(5):425-30. PubMed ID: 1770471
[TBL] [Abstract][Full Text] [Related]
18. [An experimental study on the mechanism of antiatherosclerotic effect of nifedipine].
Xu ZC
Zhonghua Xin Xue Guan Bing Za Zhi; 1993 Jun; 21(3):173-5, 188. PubMed ID: 8243235
[TBL] [Abstract][Full Text] [Related]
19. Effect of the nifedipine-atenolol association on arterial myocyte migration and proliferation.
Corsini A; Quarato P; Raiteri M; Paubert-Braquet M; Nguyen G; Picquot S; Bourgain RH; Fumagalli R; Paoletti R
Pharmacol Res; 1993; 27(4):299-307. PubMed ID: 8367379
[TBL] [Abstract][Full Text] [Related]
20. The effects of bepridil compared with calcium antagonists on rat and rabbit aorta.
Winslow E; Farmer S; Martorana M; Marshall RJ
Eur J Pharmacol; 1986 Nov; 131(2-3):219-28. PubMed ID: 3493158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
